[1] Pennathur A,Gibson MK,Jobe BA,et al. Oesophageal carcinoma[J].Lancet,2013,381(9864):400-412.DOI:10.1016/S0140-6736(12)60643-6.
[2] Wu J,Chen QX,Teng LS,et al. Prognostic significance of positive circumferential resection margin in esophageal cancer:a systematic review and meta-analysis[J].Ann Thorac Surg,2014,97(2):446-453.DOI:10.1016/j.athoracsur.2013.10.043.
[3] R sch T.Endosonographic staging of gastric cancer:a review of literature results[J].Gastrointest Endosc Clin N Am,1995,5(3):549-557.
[4] Kelly S,Harris KM,Berry E,et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma[J].Gut,2001,49(4):534-539.DOI:10.1136/gut.49.4.534.
[5] Preston SR,Clark GWB,Martin IG,et al. Effect of endoscopic ultrasonography on the management of 100 consecutive patients with oesophageal and junctional carcinoma[J].Br J Surg,2003,90(10):1220-1224.DOI:10.1002/bjs.4268.
[6] Wakelin SJ,Deans C,Crofts TJ,et al. A comparison of computerised tomography,laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma[J].Eur J Radiol,2002,41(2):161-167.DOI:10.1016/S0720-048X (01)00418-1.
[7] Lee G,I H,Kim SJ,et al. Clinical implication of PET/MR imaging in preoperative esophageal cancer staging:comparison with PET/CT,endoscopic ultrasonography,and CT[J].J Nucl Med,2014,55(8):1242-1247.DOI:10.2967/jnumed.114.138974.
[8] Rice TW.Clinical staging of esophageal carcinoma. CT,EUS,and PET[J].Chest Surg Clin N Am,2000,10(3):471-485.
[9] Riddell AM,Allum WH,Thompson JN,et al. The appearances of oesophageal carcinoma demonstrated on high-resolution,T2-weighted MRI,with histopathological correlation[J].Eur Radiol,2007,17(2):391-399.DOI:10.1007/s00330-006-0363-6.
[10] Riddell AM,Hillier J,Brown G,et al. Potential of surface-coil MRI for staging of esophageal cancer[J].AJR Am J Roentgenol,2006,187(5):1280-1287.DOI:10.2214/AJR.05.0559.
[11] Koh DM,Collins DJ.Diffusion-weighted MRI in the body:applications and challenges in oncology[J].AJR Am J Roentgenol,2007,188(6):1622-1635.DOI:10.2214/AJR.06.1403.
[12] Sakurada A,Takahara T,Kwee TC,et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer[J].Eur Radiol,2009,19(6):1461-1469.DOI:10.1007/s00330-008-1291-4.
[13] Takashima S,Takeuchi N,Shiozaki H,et al. Carcinoma of the esophagus:CT vs. MR imaging in determining resectability[J].AJR Am J Roentgenol,1991,156(2):297-302.DOI:10.2214/ajr.156.2.1898802.
[14] Petrillo R,Balzarini L,Bidoli P,et al. Esophageal squamous cell carcinoma:MRI evaluation of mediastinum[J].Gastrointest Radiol,1990,15(4):275-278.
[15] Van Vliet EPM,Heijenbrok-Kal MH,Hunink MGM,et al. Staging investigations for oesophageal cancer:a meta-analysis[J].Br J Cancer,2008,98(3):547-557.DOI:10.1038/sj.bjc.6604200.
[16] Alper F,Turkyilmaz A,Kurtcan S,et al. Effectiveness of the STIR turbo spin-echo sequence MR imaging in evaluation of lymphadenopathy in esophageal cancer[J].Eur J Radiol,2011,80(3):625-628.DOI:10.1016/j.ejrad.2010.08.003.
[17] Nishimura H,Tanigawa N,Hiramatsu M,et al. Preoperative esophageal cancer staging:magnetic resonance imaging of lymph node with ferumoxtran-10,an ultrasmall superparamagnetic iron oxide[J].J Am Coll Surg,2006,202(4):604-611.DOI:10.1016/j.jamcollsurg.2005.12.004.
[18] Mizowaki T,Nishimura Y,Shimada Y,et al. Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer:evaluation by computed tomography and magnetic resonance imaging[J].Int J Radiat Oncol Biol Phys,1996,36(5):1091-1098.DOI:10.1016/S0360-3016(96)00425-7.
[19] Sillah K,Williams LR,Laasch HU,et al. Computed tomography overestimation of esophageal tumor length:implications for radiotherapy planning[J].World J Gastrointest Oncol,2010,2(4):197-204.DOI:10.4251/wjgo.v2.i4.197.
[20] Taylor FG,Quirke P,Heald RJ,et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence:5-year follow-up results of the mercury study[J].J Clin Oncol,2014,32(1):34-43.DOI:10.1200/JCO.2012.45.3258.
[21] Buyyounouski MK,Horwitz EM,Price RA,et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment[J].Int J Radiat Oncol Biol Phys,2004,58(3):743-749.DOI:10.1016/S0360-3016(03)01617-1.
[22] Hou DL,Shi GF,Gao XS,et al. Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma[J].Radiat Oncol,2013,8:169.DOI:10.1186/1748-717X-8-169.
[23] Fujitani K,Mano M,Hirao M,et al. Posttherapy nodal status,not graded histologic response,predicts survival after neoadjuvant chemotherapy for advanced gastric cancer[J].Ann Surg Oncol,2012,19(6):1936-1943.DOI:10.1245/s10434-011-2165-6.
[24] Van Hagen P,Hulshof MCCM,Van Lanschot JJB,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088.
[25] Rohatgi P,Swisher SG,Correa AM,et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response[J].Cancer,2005,104(11):2365-2372.DOI:10.1002/cncr.21439.
[26] Berger AC,Farma J,Scott WJ,et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival[J].J Clin Oncol,2005,23(19):4330-4337.DOI:10.1200/JCO.2005.05.017.
[27] Van Heijl M,Omloo JM,Van Berge Henegouwen MI,et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer[J].Ann Surg,2011,253(1):56-63.DOI:10.1097/SLA.0b013e3181f66596.
[28] Urba SG,Orringer MB,Turrisi A,et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J].J Clin Oncol,2001,19(2):305-313.DOI:10.1200/JCO.2001.19.2.305.
[29] Stahl M,Stuschke M,Lehmann N,et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J].J Clin Oncol,2005,23(10):2310-2317.DOI:10.1200/JCO.2005.00.034.
[30] Bedenne L,Michel P,Bouché O,et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus:FFCD 9102[J].J Clin Oncol,2007,25(10):1160-1168.DOI:10.1200/JCO.2005.04.7118.
[31] Ishikura S,Nihei K,Ohtsu A,et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus[J].J Clin Oncol,2003,21(14):2697-2702.DOI:10.1200/JCO.2003.03.055.
[32] Herskovic A,Martz K,Al-Sarraf M,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J].N Engl J Med,1992,326(24):1593-1598.DOI:10.1056/NEJM199206113262403.
[33] Kesler KA,Helft PR,Werner EA,et al. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone[J].Ann Thorac Surg,2005,79(4):1116-1121.DOI:10.1016/j.athoracsur.2004.08.042.
[34] Wang QF,Yu SF,Xiao ZF,et al. Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy[J].Radiat Oncol,2015,10:142.DOI:10.1186/s13014-015-0450-4.
[35] Aoyagi T,Shuto K,Okazumi S,et al. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer[J].Dig Surg,2011,28(4):252-257.DOI:10.1159/000328770.
[36] Imanishi S,Shuto K,Aoyagi T,et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma[J].Dig Surg,2013,30(3):240-248.DOI:10.1159/000351435.
[37] George ML,Dzik-Jurasz AS,Padhani AR,et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer[J].Br J Surg,2001,88(12):1628-1636.DOI:10.1046/j.0007-1323.2001.01947.x.
[38] Ah-See MLW,Makris A,Taylor NJ,et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer[J].Clin Cancer Res,2008,14(20):6580-6589.DOI:10.1158/1078-0432.CCR-07-4310.
[39] Le Bihan D,Breton E,Lallemand D,et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging[J].Radiology,1988,168(2):497-505.DOI:10.1148/radiology.168.2.3393671.
[40] Guo Y,Cai YQ,Cai ZL,et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging[J].J Magn Reson Imaging,2002,16(2):172-178.DOI:10.1002/jmri.10140.
[41] Gauvain KM,McKinstry RC,Mukherjee P,et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging[J].AJR Am J Roentgenol,2001,177(2):449-454.DOI:10.2214/ajr.177.2.1770449.
[42] Thoeny HC,De Keyzer F,Vandecaveye V,et al. Effect of vascular targeting agent in rat tumor model:dynamic contrast-enhanced versus diffusion-weighted MR imaging[J].Radiology,2005,237(2):492-499.DOI:10.1148/radiol.2372041638.
[43] Thoeny HC,Ross BD.Predicting and monitoring cancer treatment response with diffusion-weighted MRI[J].J Magn Reson Imaging,2010,32(1):2-16.DOI:10.1002/jmri.22167.